Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
Although improved prophylaxis with post-transplant cyclophosphamide has reduced the chances of graft-vs-host disease developing, the problem has not disappeared entirely, says Antonio Jimenez Jimenez, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Read More
Improved GVHD Prophylaxis Has Broadened the Donor Pool for Stem Cell Transplants, Says Researcher
July 6th 2025Less emphasis on full HLA matching means clinicians can find an appropriate donor for any patient, says Antonio Jimenez Jimenez, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and a leading stem cell transplant researcher.
Read More
Survey of Health-System Pharmacy Directors Has Mixed Message About Role of Health-System Pharmacists
June 26th 2025Independent prescribing by health system pharmacists has decreased, but a survey shows greater involvement in emergency departments and an expanding role for pharmacy technicians.
Read More
A Progress Report on Chronic GVHD. The Grades Are Not So Great
June 24th 2025There has been no or some progress in most areas since a National Institute of Health consensus development project in 2020, according to a group of experts. But exception is important: Prevention of moderate or severe chronic graft-vs.-host disease.
Read More
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More